Clearpoint Neuro (CLPT) Q2 2025 earnings summary

Executive summary

• Achieved record Q2 2025 revenue of $9.2 million, up 17% year-over-year, driven by growth in neurosurgery navigation, biologics, and drug delivery segments.

• Entered a new growth phase, "Fast Forward," with a focus on cell and gene therapy delivery, workflow efficiency, and global expansion.

• Cash and cash equivalents reached $41.5 million as of June 30, 2025, following $30 million in note financing and $3.3–$3.5 million in equity offerings.

• Net loss widened to $5.8 million for Q2 2025, up from $4.4 million in Q2 2024, reflecting higher R&D, G&A, and sales expenses.

• Supporting over 60 biologics and drug delivery partners and expanding preclinical and global operations.

Financial highlights

• Q2 2025 revenue was $9.2 million, up from $7.9 million in Q2 2024; product revenue grew 21% to $6.0 million, service revenue rose 10% to $3.2 million.

• Gross margin was 60% in Q2 2025, down from 63% in Q2 2024, due to higher inventory reserves.

• Operating expenses increased 16% to $11.2 million, mainly from R&D and personnel costs.

• Net loss per share was $(0.21) in Q2 2025, compared to $(0.16) in Q2 2024.

• Cash used in operating activities for the first half of 2025 was $8.7 million.

Outlook and guidance

• Reaffirmed full-year 2025 revenue guidance of $36.0 million to $41.0 million.

• Expecting 15–20 new site activations in 2025, with 11–16 in the second half, and additional cell and gene therapy platforms to be approved in the next 2–3 years.

• Management believes current cash balances are sufficient to support operations for at least the next twelve months.

• Planning to accelerate new site activations and expand regulatory clearances in Canada, Japan, and China.

• Growth opportunities depend on partners' clinical and regulatory progress and may be impacted by macroeconomic trends.